Peptide Inhibitors Targeting Cyclin D Groove for CDK4 Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CDK inhibitors are non-specific and often cause toxicities due to their broad inhibition of cyclin-dependent kinases, including transcriptional CDKs, which are essential for normal cellular functions, limiting their therapeutic potential in cancer treatment.

Innovation Solution

Development of peptide inhibitors that target the cyclin D protein by generating in silico models and altering peptide structures to enhance affinity, specifically inhibiting the CDK4/cyclin D complex, thereby reducing off-target effects on other cyclin-dependent kinases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If ATP competitive CDK inhibitors are used to inhibit CDK activity, then anti-tumor efficacy is improved, but specificity is worsened leading to toxicities from broad inhibition of transcriptional CDKs

Engineering Contradiction:

Improveanti-tumor efficacyVSAvoidtoxicities from broad inhibition

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and targets only the cyclin D binding groove interface, isolating this specific interaction from other CDK-cyclin interactions. By designing peptides that specifically block the cyclin D binding groove without affecting ATP binding or transcriptional CDKs, the harmful broad inhibition is removed while preserving anti-tumor efficacy against G1/S phase CDKs

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention applies local quality by creating inhibitors with highly specific binding characteristics for the cyclin D binding groove. The peptide inhibitors are designed with specific amino acid sequences (e.g., HAKRRLIF, SAKRRLFG) that match the cyclin groove binding interface, providing localized and selective inhibition only at this site while leaving other CDK activities unaffected

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If cyclin groove inhibitors are designed to be highly specific for CDK4/cyclin D, then selectivity is improved, but manufacturing complexity increases due to peptide synthesis requirements

Engineering Contradiction:

Improveoff-target effectsVSAvoidpeptide synthesis complexity

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The invention applies parameter changes by systematically modifying peptide sequences to optimize binding affinity and selectivity. Small changes in amino acid composition (e.g., HAKRRLIF vs SAKRRLFG) are used to tune the binding characteristics for different cyclin variants, achieving high selectivity through incremental parameter optimization rather than complex structural designs

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9328139B2Cyclin based inhibitors of CDK2 and CDK4

Publication Date: 2016.05.03 UNIVERSITY OF SOUTH CAROLINA

AI summary

Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.